Published in Proc Natl Acad Sci U S A on August 16, 2010
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology (2014) 1.87
Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat Struct Mol Biol (2011) 1.68
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A (2013) 1.67
Structural and functional studies of LRP6 ectodomain reveal a platform for Wnt signaling. Dev Cell (2011) 1.50
Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling. Cold Spring Harb Perspect Biol (2012) 1.43
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway. PLoS One (2011) 1.27
LRP5 and LRP6 in development and disease. Trends Endocrinol Metab (2013) 1.21
Inducible progenitor-derived Wingless regulates adult midgut regeneration in Drosophila. EMBO J (2012) 1.18
Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther (2015) 1.14
Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts. J Biol Chem (2012) 1.14
Wnt activity and basal niche position sensitize intestinal stem and progenitor cells to DNA damage. EMBO J (2015) 1.04
Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene (2014) 1.03
Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet (2012) 1.00
Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. PLoS One (2013) 0.97
Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95
Wnt/β-catenin Signaling in Normal and Cancer Stem Cells. Cancers (Basel) (2011) 0.94
Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem (2014) 0.91
WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. Oncotarget (2014) 0.91
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A (2014) 0.90
Pathogenic role of the Wnt signaling pathway activation in laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci (2013) 0.90
Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo. FEBS Lett (2011) 0.89
Frizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int J Cancer (2012) 0.89
Remodeling of endogenous mammary epithelium by breast cancer stem cells. Stem Cells (2012) 0.88
Both canonical and non-canonical Wnt signaling independently promote stem cell growth in mammospheres. PLoS One (2014) 0.88
Wnt signaling in bone and muscle. Bone (2015) 0.86
Updating the Wnt pathways. Biosci Rep (2014) 0.86
Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene (2013) 0.86
Use of a molecular genetic platform technology to produce human Wnt proteins reveals distinct local and distal signaling abilities. PLoS One (2013) 0.86
The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells. PLoS One (2013) 0.85
Receptor heterodimerization as a novel mechanism for the regulation of Wnt/β-catenin signaling. J Cell Sci (2014) 0.85
Oral epithelial stem cells - implications in normal development and cancer metastasis. Exp Cell Res (2014) 0.84
Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition. PLoS One (2013) 0.83
The osteocyte as a therapeutic target in the treatment of osteoporosis. Ther Adv Musculoskelet Dis (2014) 0.82
Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro. Bonekey Rep (2015) 0.82
Planar cell polarity aligns osteoblast division in response to substrate strain. J Bone Miner Res (2015) 0.81
Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia? Curr Oncol (2016) 0.81
Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy. Biomark Res (2013) 0.80
Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors. ACS Med Chem Lett (2016) 0.79
A new tumour suppressor enters the network of intestinal progenitor cell homeostasis. EMBO J (2012) 0.79
Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci (2015) 0.77
Synaptic Wnt/GSK3β Signaling Hub in Autism. Neural Plast (2016) 0.76
Lrp5 Has a Wnt-Independent Role in Glucose Uptake and Growth for Mammary Epithelial Cells. Mol Cell Biol (2015) 0.75
Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer. Cancers (Basel) (2016) 0.75
The SIAH E3 ubiquitin ligases promote Wnt/β-catenin signaling through mediating Wnt-induced Axin degradation. Genes Dev (2017) 0.75
Wnt/β-catenin Signaling in Osteoarthritis and in Other Forms of Arthritis. Curr Rheumatol Rep (2017) 0.75
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol (2004) 24.63
Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 18.31
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature (2001) 7.44
LDL-receptor-related proteins in Wnt signal transduction. Nature (2000) 6.94
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet (2001) 6.56
LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development (2004) 6.21
Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol (2001) 5.95
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science (2007) 5.45
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet (2001) 4.97
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science (2007) 4.27
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell (2007) 4.21
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem (2005) 4.13
Structure of the LDL receptor extracellular domain at endosomal pH. Science (2002) 4.06
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell (2004) 3.30
Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta activity. Dev Cell (2003) 2.95
Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development (2004) 2.84
LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem (2006) 2.09
Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res (2005) 2.08
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene (2006) 2.05
Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol (2006) 1.99
Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell (2003) 1.99
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene (2005) 1.82
The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol (2004) 1.77
A novel mechanism for Wnt activation of canonical signaling through the LRP6 receptor. Mol Cell Biol (2003) 1.67
Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. J Biol Chem (2010) 1.63
Wnt-independent activation of beta-catenin mediated by a Dkk1-Fz5 fusion protein. Biochem Biophys Res Commun (2005) 1.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Directed differentiation of embryonic stem cells into motor neurons. Cell (2002) 9.76
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature (2009) 9.15
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 7.88
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics (2004) 6.78
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Cyclin E ablation in the mouse. Cell (2003) 5.58
The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 5.43
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell (2009) 4.52
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res (2003) 4.29
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell (2003) 4.13
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med (2002) 4.00
PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A (2008) 3.87
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell (2003) 3.86
Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J Biol (2002) 3.85
Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron (2003) 3.76
A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell (2002) 3.73
Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer (2006) 3.72
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature (2012) 3.44
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol (2006) 3.39
Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res (2004) 3.37
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Akt-regulated pathways in prostate cancer. Oncogene (2005) 3.35
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell (2003) 3.29
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res (2009) 3.21
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle (2009) 3.14
Brief screening instrument for post-traumatic stress disorder. Br J Psychiatry (2002) 3.09
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res (2003) 3.09
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med (2010) 2.86
Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol (2002) 2.86
Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol (2005) 2.84
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther (2011) 2.73
Phylogeny and ancient DNA of Sus provides insights into neolithic expansion in Island Southeast Asia and Oceania. Proc Natl Acad Sci U S A (2007) 2.60
A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res (2007) 2.52
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov (2013) 2.52
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res (2005) 2.49
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov (2013) 2.43
Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell (2011) 2.34
The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood (2006) 2.33
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
Efficient generation and mapping of recessive developmental mutations using ENU mutagenesis. Nat Genet (2002) 2.30